Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported its highest quarterly revenue growth in 16 quarters at 16.6% YoY for Q4 FY26, with revenue of Rs. 703 crore. Full year FY26 revenue grew 12.2% to Rs. 2,763 crore, driven by strong volume growth of 12.9% in sample volumes during Q4. The company added 14 new laboratories and over 1,100 collection centers during the year, expanding its network to 7,727 Patient Service Centers and 13,935 Pick-up Points. Normalized PAT grew 17.9% to Rs. 532 crore, while EBITDA margin remained stable at 28.3% for FY26. Key highlights include the launch of Sovaaka (AI-powered precision health screening), hosting the first Medllumina international medical conference, and strong SwasthFit bundled offerings contribution rising to 27% of revenue.
The company demonstrates solid operational execution with strong volume growth and geographic expansion, though Q4 FY26 EBITDA margin of 26.6% showed pressure compared to 28.1% in Q4 FY25. The continued network expansion and premium wellness brand launch position the company for sustained growth, though investors should monitor margin sustainability amid competitive dynamics.